Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001949183 | SCV002211391 | uncertain significance | Brugada syndrome 5 | 2021-04-28 | criteria provided, single submitter | clinical testing | Experimental studies and prediction algorithms are not available or were not evaluated, and the functional significance of this variant is currently unknown. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. This variant has not been reported in the literature in individuals with SCN1B-related conditions. This variant is present in population databases (rs765702440, ExAC 0.01%). This sequence change replaces threonine with proline at codon 191 of the SCN1B protein (p.Thr191Pro). The SCN1B gene has multiple clinically relevant transcripts. This variant occurs in alternate transcript NM_001037.4, and corresponds to NM_199037.4:c.*5141A>C in the primary transcript. |
Ambry Genetics | RCV003375476 | SCV004096811 | uncertain significance | Cardiovascular phenotype | 2023-09-06 | criteria provided, single submitter | clinical testing | The p.T191P variant (also known as c.571A>C), located in coding exon 4 of the SCN1B gene, results from an A to C substitution at nucleotide position 571. The threonine at codon 191 is replaced by proline, an amino acid with highly similar properties. This amino acid position is conserved. In addition, the in silico prediction for this alteration is inconclusive. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |